Alzheimer’s disease (AD), one of the most prevalent neurodegenerative diseases, is associated with multiple pathological factors such as metal ion dyshomeostasis, proteopathy, oxidative stress, neuroinflammation, and neurotransmitter deficiencies. We develop novel therapeutic and diagnostic agents for AD based on multifunctional compounds that interact with amyloid β (Aβ) species and also target other pathologies. We have developed multifunctional compounds with high affinity for soluble and insoluble Aβ aggregates and metal ions, show enhanced antioxidant ability, alleviate copper-induced Aβ cytotoxicity, and reduce neuroinflammation. Multifunctional compounds with high affinity for metal ions and soluble Aβ aggregates can be radiolabeled with the 64Cu radionuclide to generate diagnostic positron emission tomograph (PET) imaging agents for AD. Importantly, through rational ligand design and tuning, we developed a series of Aβ-binding multifunctional compounds that can form thermodynamically stable and kinetically inert Cu complexes. Furthermore, the 64Cu radiolabeled PET imaging tracers are able to cross the blood-brain barrier and stain Aβ aggregates in vivo. Such novel theranostic agents for AD could be applied for early diagnosis of AD, as well as treatment to prevent the onset of severe cognitive impairment and improve the life quality of AD patients.

Development of novel theranostic agents for Alzheimer's disease

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.